



MEDICAL PRODUCT ALERT

DRAP ALERT NO. N° I/S/06-25-46

Recall of Substandard “Tovir 0.5mg Tablet” Batch No. 55 Manufactured by M/s Adamjee Pharmaceuticals (Pvt.) Ltd, Karachi.

Date: 17th June, 2025

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Federal Government Analyst, CDL, Karachi vide test report No. KQ-2-25-000025 has declared the sample of subject mentioned batch of the product as of ‘**Substandard**’ quality. Details of the CDL test report are as under:

S. No.	Product Details	Batch No.	Manufactured by	CDL Test Result
01	Tovir 0.5mg Tablet Each tablet contains: Clonazepam.....0.5mg Reg # 080335	55	M/s Adamjee Pharmaceuticals (Pvt.) Ltd., No. 39, Sector 15, Korangi Industrial Area, Karachi.	‘ Substandard ’ on the basis of Content Uniformity Test.

Risk Statement:

The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population.

Action initiated: -

The field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores: -

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).



DRAP, Islamabad



+92 051 9255969



gsms@dra.gov.pk



Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this [link](#). Further information of reporting problems to DRAP is available on this [link](#).

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.



Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج



DRAP, Islamabad



+92 051 9255969



gsms@dra.gov.pk